Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	51.5	50.58	47.68	50.83	45.85	52.61
Revenue Growth (YoY)	10.65%	6.09%	-6.20%	10.87%	-12.85%	-21.98%
Cost of Revenue	20.48	20.83	19.39	14.99	12.96	20.36
Gross Profit	31.02	29.75	28.29	35.84	32.89	32.25
Selling, General & Admin	34.98	31.75	52.88	53.48	55.89	64.34
Research & Development	15.49	13.1	17.48	17.05	19.89	20.57
Operating Expenses	50.47	44.85	70.36	70.52	75.78	84.92
Operating Income	-19.45	-15.1	-42.07	-34.68	-42.89	-52.67
Interest Expense / Income	10.18	7.46	12.44	22.46	13.02	9.32
Other Expense / Income	-1.11	-14.94	-0.1	13.4	-0.13	4.26
Pretax Income	-28.52	-7.63	-54.41	-70.54	-55.78	-66.25
Income Tax	0.25	0.25	0	0	0	0
Net Income	-28.77	-7.87	-54.41	-70.54	-55.78	-66.25
Shares Outstanding (Basic)	74	61	49	38	34	25
Shares Outstanding (Diluted)	74	61	49	38	34	25
Shares Change	-0.24%	25.69%	27.99%	13.15%	32.71%	22.34%
EPS (Basic)	-0.43	-0.13	-1.12	-1.85	-1.66	-2.61
EPS (Diluted)	-0.43	-0.13	-1.12	-1.85	-1.66	-2.61
Free Cash Flow	-26.6	-7.38	-10.84	-33.89	-45.98	-60.87
Free Cash Flow Per Share	-0.36	-0.12	-0.22	-0.89	-1.37	-2.40
Gross Margin	60.23%	58.82%	59.34%	70.51%	71.72%	61.30%
Operating Margin	-37.77%	-29.86%	-88.23%	-68.22%	-93.55%	-100.11%
Profit Margin	-55.85%	-15.56%	-114.11%	-138.77%	-121.67%	-125.92%
Free Cash Flow Margin	-51.65%	-14.58%	-22.74%	-66.67%	-100.28%	-115.71%
EBITDA	-17.12	1.18	-39.58	-45.11	-39.32	-54.02
EBITDA Margin	-33.24%	2.34%	-83.01%	-88.75%	-85.76%	-102.69%
Depreciation & Amortization	1.23	1.35	2.39	2.96	3.44	2.91
EBIT	-18.35	-0.16	-41.97	-48.08	-42.76	-56.93
EBIT Margin	-35.62%	-0.32%	-88.02%	-94.58%	-93.26%	-108.21%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).